Equity Overview
Price & Market Data
Price: $22.20
Daily Change: +$2.54 / 11.44%
Range: $18.53 - $23.49
Market Cap: $1,075,108,352
Volume: 3,224,835
Performance Metrics
1 Week: 5.64%
1 Month: 10.16%
3 Months: 5.64%
6 Months: -7.90%
1 Year: -0.36%
YTD: -2.62%
Company Details
Employees: 62
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.